Guardant Health Showcases Data at ESMO 2021 Demonstrating Utility of Guardant360 ® Liquid Biopsy to Obtain Comprehensive Molecular Information to Guide Targeted Therapy Options for Late-Stage Cancers
Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, share data highlighting molecular targets of importance, treatment resistance patterns, and advantages of using the Guardant360® liquid biopsy test to help improve the management of advanced solid cancers at the European Society for Medical Oncology (ESMO) 2021 virtual congress on September 16-21.
“While precision oncology has made a meaningful difference in improving clinical outcomes for highly prevalent cancers, such as non-small cell lung, colorectal, and breast, there remains a subset of patients who don’t respond to currently available treatments,” said Craig Eagle, MD, Guardant Health Chief Medical Officer. “It is gratifying to be able to work with the oncology community to analyze the molecular information generated from our liquid biopsy tests to continue to increase our understanding of possible new targets and more personalized treatments which can potentially improve overall survival of these hard-to-treat cancers in a more meaningful way.”
Guardant INFORM™ Liquid Biopsy Dataset Shows No Clear Standard of Care and Unmet Need for Patients with HER2+ Metastatic Colorectal Cancer
Title | ePoster | Presenter |
Characteristics and treatment patterns among patients with HER2-amplified advanced/metastatic colorectal cancer (mCRC): A clinical-genomic database study | 439P | John Strickler |
Guardant360® Liquid Biopsy Reveals Molecular Insights Impacting Outcomes in Patients with Unresectable and Early-Onset (<50 years) Metastatic Colorectal Cancer
Title | ePoster | Presenter |
Molecular features in liquid biopsy of early (EO) and late-onset colorectal cancer (LO) | 500P | Julia Alcaide-Garcia |
Mutational landscape in synchronous unresectable metastatic colorectal cancer (mCRC) according to upfront primary tumour resection (UPTR) | 503P | Manuel Benavides |
Guardant360® Liquid Biopsy Reveals Treatment Resistance Patterns and Therapeutic Targets for the Management of Advanced Cancers Including Non-Small Cell Lung and Pancreatic
Title | ePoster | Presenter |
First-results of the CLIMB360 study, a prospective molecular screening program across multiple cancer types based on circulating tumor DNA (ctDNA) | 92P | Javier Garcia-Corbacho |
Pre-existing and acquired mechanisms of resistance to lorlatinib in previously treated patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC) | 1196P | Ben J. Solomon |
Cell-free DNA dominant clone allele frequency associates with poor outcomes in advanced pancreatic cancer | 1483P | Pedro Uson Junior |
About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2020 and in its other reports filed with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q for the periods ended March 31, 2021 and June 30, 2021. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210915005307/en/
Contact information
Investor Contact:
Carrie Mendivil
investors@guardanthealth.com
Media Contact:
Anna Czene
press@guardanthealth.com
Julie Johnson
julie.johnson@uncappedcommunications.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HubHead Corp. Acquires DataSeer Inc. Assets to Expand its Vertical AI Capabilities18.4.2024 22:15:00 CEST | Press release
In a strategic move to bolster its vertical AI strategy for asset-intensive industries, HubHead Corp. announced today its acquisition of the assets of DataSeer, Inc. The acquisition adds to HubHead’s portfolio of tools focused on using AI and machine learning to improve asset and maintenance master data and assisting asset-intensive businesses in digitizing data to create digital twins. HubHead’s software improves the effectiveness of our customers’ Enterprise Asset Management (EAM) and CMMS solutions. As a frontrunner in the application of AI to enhance asset and maintenance master data quality, HubHead is dedicated to collaborating with customers to provide innovative software-as-a-service (SaaS) solutions. AI makes it easier for asset-intensive businesses to ensure their maintenance and operations, and EAM solutions are more efficient, reliable, and prepared for future initiatives. Greg Dee, CEO of HubHead, emphasized the importance of AI tools to create the asset and maintenance ma
Banco Popular Launches a New Campaign 'We Follow Your Rhythm'; Introduces Audio Branding18.4.2024 20:29:00 CEST | Press release
Puerto Rico is a recognized global platform for musical talent, with a variety of rhythms and genres representing its cultural wealth. Rooted in that influence, Banco Popular announced a new campaign titled “We Follow Your Rhythm”. The Bank used the analogy of music to capture the diversity of its customers, the wide range of their banking preferences and the ways that Popular meets those banking needs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240418724939/en/ Tommy Torres (Photo: Business Wire) “For the past 130 years Popular has evolved with cultural, social, and economic changes to ensure it serves optimally and efficiently. We have always moved at the pace of our clients, understanding their preferences, and constantly transforming our offering to meet their needs so they can carry out their transactions in an agile and simple way,” said Ignacio Álvarez, president and CEO of Popular. “We Follow Your Rhythm” positio
B2Broker Increases Leverage on Major FX Pairs to 1:20018.4.2024 18:06:00 CEST | Press release
Leading Prime of Prime liquidity provider B2Broker is committed to quality, always listening to their clients' needs to provide them with the best possible tools to bring in more end users and gain a competitive edge in the industry. In this regard, B2Broker announces the rise of the leverage to 1:200 for major FX pairs, thereby reducing the margin requirements from 1% to 0.5%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240418556608/en/ B2Broker increases leverage on major FOREX pairs to 1:200 and to 1:50 for BTC/USD and ETH/USD pairs, enhancing the market position of their clients. (Graphic: Business Wire) Additionally, with the cryptocurrency market thriving and traders’ demands for higher leverage growing, the company has increased leverage up to 1:50 for BTCUSD and ETHUSD, reducing margin requirements from 10% to 2% and significantly enhancing the clients' market position. Additional Information about B2Broker Liquid
Proemion Holding GmbH Agrees to Acquire TrendMiner NV to Expand Industrial Asset-Monitoring and Analytics Platform18.4.2024 17:32:00 CEST | Press release
Proemion Holding GmbH, a global provider of advanced data and analytics technology for mobile industrial assets, announced an agreement to acquire TrendMiner NV, an industrial analytics company, from Software AG. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417486875/en/ The spinout and acquisition of TrendMiner, based in Belgium, will significantly expand Proemion’s existing analytics capabilities for critical industrial equipment, which help equipment manufacturers and operators gather machine data remotely and continuously to maximize uptime and performance. TrendMiner produces a complementary, web-based, self-service analytics platform for monitoring critical equipment inside complex industrial environments. The technology allows teams to collaborate, learn and improve the overall performance of all production. TrendMiner’s technology is used across industries including chemicals, oil and gas, pharmaceuticals, power
Kinsted Wealth Selects Objectway for Enhanced and Fully Integrated Client and Investment Management Platform to Drive Growth18.4.2024 15:28:00 CEST | Press release
Objectway, global Top 100 FinTech provider of as-a-service software and services to banks, wealth and asset managers, has partnered with Kinsted Wealth, a Calgary (CAN) based independent wealth manager serving private individuals and institutional investors. Objectway will help Kinsted Wealth manage their business in a fully integrated and centralised manner, ultimately accelerating the growth of its discretionary business and external advisor network. This new client partnership follows the recent addition of leading digital wealth solutions provider Nest Wealth to Objectway, building on the momentum of the Group’s active expansion and operational capability in Canada. Objectway's digital front-end will deliver improved client experience for Kinsted Wealth by providing investors with omnichannel interaction, client engagement and front-office productivity, supported by an online portal and mobile apps for investors. This solution will enable Kinsted Wealth to improve client experience